231 related articles for article (PubMed ID: 37178426)
61. Subtype-DCC: decoupled contrastive clustering method for cancer subtype identification based on multi-omics data.
Zhao J; Zhao B; Song X; Lyu C; Chen W; Xiong Y; Wei DQ
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36702755
[TBL] [Abstract][Full Text] [Related]
62. Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H; Chen L; Zhang M; Luo Y; Ma X
Gynecol Oncol; 2021 Oct; 163(1):171-180. PubMed ID: 34275655
[TBL] [Abstract][Full Text] [Related]
63. Refining molecular subtypes and risk stratification of ovarian cancer through multi-omics consensus portfolio and machine learning.
Zhang J; He S; Ying H
Environ Toxicol; 2024 Mar; ():. PubMed ID: 38480676
[TBL] [Abstract][Full Text] [Related]
64. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
65. Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response.
Tang C; Yu M; Ma J; Zhu Y
J Transl Med; 2021 May; 19(1):205. PubMed ID: 33985530
[TBL] [Abstract][Full Text] [Related]
66. Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures.
Han X; Lu H; Tang X; Zhao Y; Liu H
Immun Inflamm Dis; 2022 Jan; 10(1):43-59. PubMed ID: 34582114
[TBL] [Abstract][Full Text] [Related]
67. Characterization of anoikis-based molecular heterogeneity in pancreatic cancer and pancreatic neuroendocrine tumor and its association with tumor immune microenvironment and metabolic remodeling.
Li N; Jia X; Wang Z; Wang K; Qu Z; Chi D; Sun Z; Jiang J; Cui Y; Wang C
Front Endocrinol (Lausanne); 2023; 14():1153909. PubMed ID: 37234801
[TBL] [Abstract][Full Text] [Related]
68. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
69. Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.
Hu R; Tao T; Yu L; Ding Q; Zhu G; Peng G; Zheng S; Yang L; Wu S
Front Cell Dev Biol; 2021; 9():809588. PubMed ID: 35223867
[TBL] [Abstract][Full Text] [Related]
70. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
[TBL] [Abstract][Full Text] [Related]
71. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
Zhang H; Wu Y; Li H; Sun L; Meng X
Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
[TBL] [Abstract][Full Text] [Related]
72. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer.
Zhu W; Wu J; Huang J; Xiao D; Li F; Wu C; Li X; Zeng H; Zheng J; Lai W; Wen X
Front Immunol; 2023; 14():1122670. PubMed ID: 37122696
[TBL] [Abstract][Full Text] [Related]
73. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
74. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Shi Y; Huang J; Hu Y; Shen Y
BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
[TBL] [Abstract][Full Text] [Related]
75. The landscape of angiogenesis subtypes for breast cancer: a comprehensive analysis based on the Cancer Genome Atlas.
Peng XF; Qin FL; Chen WJ; Zhang H; Mai ZY; Zeng J
J BUON; 2021; 26(5):1975-1990. PubMed ID: 34761608
[TBL] [Abstract][Full Text] [Related]
76. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
77. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
78. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract][Full Text] [Related]
79. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
80. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
